Imagine grappling with a condition where your own immune system stealthily disarms the very connection that allows you to move, speak, or even breathe—this is the reality for an estimated 20 in every 100,000 Americans living with Myasthenia Gravis.
Key Takeaways
- Myasthenia gravis (MG) has a prevalence of approximately 20 per 100,000 people in the United States
- Annual incidence of MG in the US is 1.7 to 21.9 per million person-years
- MG affects women more frequently than men before age 40, with a female-to-male ratio of 3.5:1
- Ptosis is the most common initial symptom in 50-60% of MG patients
- Diplopia occurs in 35-50% at presentation
- Limb weakness affects 30-40% initially
- Acetylcholine receptor (AChR) antibody test positive in 85% generalized MG
- Single-fiber EMG (SFEMG) sensitivity 95-99% for MG
- Repetitive nerve stimulation (RNS) decrement >10% in 75% generalized MG
- Pyridostigmine first-line in 90% of MG patients
- Thymectomy improves outcomes in 70% AChR-positive under 60
- Prednisone induces remission in 70-80% but relapse on taper
- Mortality from MG crisis now <5% with ICU care
- Spontaneous remission in ocular MG 40-50% within 2 years
- 5-year survival 95% in modern era
Myasthenia Gravis is a rare autoimmune disease with fluctuating muscle weakness symptoms.
Diagnosis
1Acetylcholine receptor (AChR) antibody test positive in 85% generalized MG
Verified2Single-fiber EMG (SFEMG) sensitivity 95-99% for MG
Verified3Repetitive nerve stimulation (RNS) decrement >10% in 75% generalized MG
Verified4Ice pack test positive (improves ptosis) in 80% ocular MG
Directional5MuSK antibody test positive in 38% of AChR-seronegative generalized MG
Single source6Edrophonium (Tensilon) test improvement in 90% but rarely used now
Verified7Chest CT detects thymoma in 12% MG patients
Verified8Anti-striational antibodies in 84% thymoma-associated MG
Verified9LRP4 antibodies detected in 0.5-8% seronegative MG
Directional10Electrophysiology abnormal in 90% ocular MG if SFEMG used
Single source11Sleep test for ptosis improvement in 60% ocular MG
Verified12Titers of AChR antibodies correlate with severity in 70%
Verified13RNS sensitivity higher in bulbar (90%) vs limb muscles (70%)
Verified14MRI thymus abnormal (hyperplasia) in 65% early-onset AChR-MG
Directional15Cell-based assays detect clustered AChR antibodies in 7% seronegative
Single source16EMG jitter >50 μs diagnostic in SFEMG for 95%
Verified17Pulmonary function tests (FVC <20 mL/kg) predict crisis risk
Verified18Anti-Titin antibodies in 20% non-thymoma MG
Verified19Neostigmine test sensitivity 75% in ocular MG
Directional20Facial RNS decrement in 50% seronegative MG
Single source21Thymus biopsy shows lymphoid follicles in 80% hyperplasia
Verified22Antibody panel (AChR, MuSK, LRP4) identifies 95% generalized MG
Verified23Quantitative MG score correlates with antibody levels
Verified24Orbital MRI normal in MG (vs Graves)
Directional25CSF normal in 100% MG (vs Guillain-Barre)
Single source26Pyridostigmine improves strength in 90% as diagnostic trial
Verified27RNS post-exercise facilitation <100% in 80% MG
Verified28Sensitivity of clinical exam alone 50-70% for MG
VerifiedDiagnosis Interpretation
Diagnosing Myasthenia Gravis is a bit like detective work, requiring a blend of clever antibody sleuthing (which catches most culprits), shrewd electrical tests to catch the disease red-handed, and a keen clinical eye to interpret the clues, because no single test tells the whole story.
Epidemiology
1Myasthenia gravis (MG) has a prevalence of approximately 20 per 100,000 people in the United States
Verified2Annual incidence of MG in the US is 1.7 to 21.9 per million person-years
Verified3MG affects women more frequently than men before age 40, with a female-to-male ratio of 3.5:1
Verified4In individuals over 50 years, MG shows a male predominance with a ratio of 1.4:1 male-to-female
Directional5Prevalence of MG in Europe ranges from 5 to 30 per 100,000 population
Single source6Late-onset MG (after age 50) accounts for 40-50% of all cases in recent decades
Verified7Ocular MG represents 15% of all MG cases at onset
Verified8Thymoma-associated MG occurs in 10-15% of patients
Verified9Incidence of MG in Norway is 1.66 per 100,000 person-years
Directional10Seronegative MG (no detectable AChR antibodies) comprises 10-15% of cases
Single source11MuSK-positive MG accounts for 5-8% of generalized MG cases
Verified12LRP4 antibodies are found in 1-4% of AChR-seronegative MG patients
Verified13Pediatric MG incidence is 1-5 per million children under 18
Verified14African Americans have a higher incidence of early-onset MG
Directional15Prevalence of MG in Japan is 13.1 per 100,000
Single source16MG incidence has doubled in the last 30 years in some populations
Verified17Familial MG occurs in less than 5% of cases
Verified18Neonatal MG transient form affects 10-20% of infants born to MG mothers
Verified19Congenital myasthenic syndromes (non-autoimmune) prevalence is 1 in 500,000
Directional20MG is more prevalent in northern latitudes
Single source21Incidence in Olmsted County, MN: 3.0 per 100,000 person-years for women
Verified22Overall MG prevalence in UK is 15 per 100,000
Verified23AChR antibody-positive MG in 80-85% of generalized cases
Verified24Early-onset MG (before 40) is 60% of cases in females
Directional25MG with thymic hyperplasia in 70-80% of non-thymoma cases
Single source26Incidence rate in Spain: 1.38 per 100,000/year
Verified27Asian populations show higher MuSK-MG prevalence (up to 40%)
Verified28MG remission rates influence epidemiology tracking
Verified29US veteran population MG prevalence higher at 32.5 per 100,000
Directional30Global MG prevalence estimated at 700,000 cases
Single sourceEpidemiology Interpretation
While globally it's a rare condition affecting roughly one person in every five thousand, myasthenia gravis is a master of disguises, frequently changing its demographic face like a capricious theater director who prefers casting women under forty and men over fifty, with its epidemiology showing as much variation across populations as its symptoms do across patients.
Prognosis
1Mortality from MG crisis now <5% with ICU care
Verified2Spontaneous remission in ocular MG 40-50% within 2 years
Verified35-year survival 95% in modern era
Verified4Thymoma-MG recurrence 10-20% post-resection
Directional5Minimal manifestation status in 50% thymectomized
Single source6Crisis incidence 10-20% lifetime
Verified7Seronegative MG worse prognosis, remission <20%
Verified8MuSK-MG more bulbar, harder to treat, remission 30%
Verified9Pregnancy exacerbation in 30%, remission 20%
Directional10Late-onset MG similar prognosis to early-onset
Single source11Quality of life MG-QOL15 score averages 20-30 mild cases
Verified12Aspiration pneumonia complication in 10% bulbar MG
Verified13Complete stable remission 10-20% long-term
Verified14Thymectomy benefit persists 85% at 3 years REPAIR trial
Directional15Cardiovascular comorbidity increases mortality 2-fold
Single source16Functional remission (no meds) 15-30% post-thymectomy
Verified17MGFA Class III-IV at 1 year predicts poor outcome
Verified18Antibody titer decline predicts improvement 60%
Verified19ICU stay average 10-14 days in crisis
Directional20Osteoporosis from steroids in 40% long-term
Single source21Employment rate 50% in treated MG patients
Verified22Visual impairment permanent in 10% ocular MG
Verified23Cancer risk elevated 2-fold in MG (thymoma 30x)
Verified24Drug-induced MG permanent in 30% cases
Directional25Pediatric MG remission 60% spontaneous or treated
Single sourcePrognosis Interpretation
Myasthenia gravis, you fickle foe, offers glimpses of hope and harsh reality in equal measure: while ICU care has tamed the mortal threat and many can chase remission, the path remains a gauntlet of potential crises, stubborn symptoms, and the sobering toll of the treatments themselves.
Symptoms
1Ptosis is the most common initial symptom in 50-60% of MG patients
Verified2Diplopia occurs in 35-50% at presentation
Verified3Limb weakness affects 30-40% initially
Verified4Bulbar symptoms (dysphagia, dysarthria) in 15-20% at onset
Directional5Fatigable weakness worsens with repeated activity in 90% of cases
Single source6Respiratory muscle weakness leads to crisis in 10-20% lifetime risk
Verified7Ocular MG symptoms bilateral in 30% at onset
Verified8Neck extensor weakness ("dropped head") in 10-15% generalized MG
Verified9Facial muscle weakness in 60% of generalized MG patients
Directional10Dysphagia present in 33% during exacerbations
Single source11Proximal > distal limb weakness pattern in 70%
Verified12Symptoms fluctuate daily, worse evenings in 80%
Verified13Heat sensitivity exacerbates symptoms in 50-70%
Verified14Infections precipitate symptoms in 65% of crises
Directional15Arm weakness more than leg in 40%
Single source16Voice fatigue (nasal speech) in 25% bulbar involvement
Verified17Chewing fatigue in 20-30% with bulbar symptoms
Verified18Sensory symptoms absent in 100% of MG cases
Verified19Reflexes preserved until late weakness in 90%
Directional20Myokymia absent, distinguishing from neuromyotonia
Single source21Cold worsens symptoms in MuSK-MG more than AChR-MG (60% vs 20%)
Verified22Blepharoptosis variability asymmetric in 50%
Verified23Limb girdle weakness predominant in 25% thymoma-MG
Verified24Crisis symptoms include dyspnea in 85%
Directional25Jaw weakness (hangs open) in 15%
Single source26Gait unsteadiness from hip girdle weakness in 35%
VerifiedSymptoms Interpretation
While a patient's day may start with droopy eyes or double vision, by evening their own limbs might betray them in a cruel symphony of weakness that plays louder with every repeated movement and often turns up the heat.
Treatment
1Pyridostigmine first-line in 90% of MG patients
Verified2Thymectomy improves outcomes in 70% AChR-positive under 60
Verified3Prednisone induces remission in 70-80% but relapse on taper
Verified4IVIG effective in 70-80% crisis, onset 1-2 weeks
Directional5Plasmapheresis rapid improvement in 75% crisis, lasts 4-6 weeks
Single source6Azathioprine steroid-sparing in 70% after 12 months
Verified7Rituximab MuSK-MG remission in 55-88%
Verified8Eculizumab reduces exacerbations by 72% in refractory AChR-MG
Verified9Mycophenolate mofetil effective in 70-80% refractory cases
Directional10Cyclosporine remission in 40-50% steroid-dependent
Single source11Methotrexate used in 20% as steroid-sparer
Verified12Efgartigimod (FcRn inhibitor) reduces IgG by 70%
Verified13Thymectomy minimally invasive in 80% cases now
Verified14IVIG dosing 2g/kg over 2-5 days for crisis
Directional15PLEX 5-7 exchanges over 10-14 days
Single source16Steroid side effects in 50% long-term (osteoporosis 30%)
Verified17Tacrolimus effective in 80% Japanese MG cohort
Verified18Biologic therapies (ritux, ecu) in 10-15% refractory
Verified19Pyridostigmine dose 30-1200mg/day titrated
Directional20Remission after thymectomy 30-50% at 5 years
Single source21Azathioprine dose 2-3mg/kg, remission 20-40%
Verified22Complement inhibitors like ravulizumab in trials
Verified23Supportive care (ventilation) in 15% crisis admissions
Verified24Vaccine avoidance during immunosuppression
Directional25Occupational therapy improves function in 60%
Single source26Beta-blockers contraindicated (worsen 20%)
VerifiedTreatment Interpretation
Myasthenia Gravis treatment is a masterclass in strategic, multi-layered artillery where we deploy a symphony of options—from first-line shields to targeted biologic missiles and careful surgical strikes—all while meticulously dodging the frequent, friendly-fire of side effects.